Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZP10068
- Development stage
- Preclinical
- Lead developer
- Alexion Pharmaceuticals
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous
01
Overview
ZP10068 is an investigational, selective, and long-acting inhibitor of Complement C3 developed by Zealand Pharma. It is a synthetic peptide therapeutic designed to target the complement pathway and inhibit the central component C3 protein of the complement cascade. The drug aims to treat a range of complement-mediated diseases associated with chronic inflammation, including rare immune-mediated disorders such as paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, myasthenia gravis, and C3 glomerulopathy. As of May 2024, ZP10068 has completed preclinical activities with plans for first-in-human clinical trials[1][2][3].
- Other names
- ZP 10068ZP10068ZP-10068
02
Targets
C3
Beyond the preview
Go deeper on ZP10068.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZP10068.